ReviewSeminars in nuclear medicine2012
Brain tumors.
Review in Seminars in nuclear medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 159 citations in OpenAlex.
- Diagnostic Accuracy of PET for Differentiating True Glioma Progression From Post Treatment-Related Changes: A Systematic Review and Meta-Analysis.Frontiers in neurology · 2021Pooled it
- Is it necessary for patients with potentially resectable esophageal squamous cell cancer to receive routine preoperative brain MRI/CT?Thoracic cancer · 2022Trial
- Article
- Article
- Nanotechnology in brain cancer treatment: The role of gold nanoparticles as therapeutic enhancers.Ibrain · 2025Review
- Personalized mRNA vaccines in glioblastoma therapy: from rational design to clinical trials.Journal of nanobiotechnology · 2024Review
- Radiosynthesis and preclinical evaluation of aEJNMMI radiopharmacy and chemistry · 2024Article
- Review of the Brain's Behaviour after Injury and Disease for Its Application in an Agent-Based Model (ABM).Biomimetics (Basel, Switzerland) · 2024Review
- Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors.Cancers · 2024Review
- Preclinical and Clinical Use of Indigenously DevelopedACS pharmacology & translational science · 2023Review
- Diagnostic accuracy of glioma pseudoprogression identification with positron emission tomography imaging: a systematic review and meta-analysis.Quantitative imaging in medicine and surgery · 2023Article
- Mathematical Assessment of Machine Learning Models Used for Brain Tumor Diagnosis.Diagnostics (Basel, Switzerland) · 2023Article
- The Role of Positron Emission Tomography and Computed Tomographic (PET/CT) Imaging for Radiation Therapy Planning: A Literature Review.Diagnostics (Basel, Switzerland) · 2022Review
- Artificial Intelligence and Precision Medicine: A New Frontier for the Treatment of Brain Tumors.Life (Basel, Switzerland) · 2022Review
- Classification of Brain Tumor from Magnetic Resonance Imaging Using Vision Transformers Ensembling.Current oncology (Toronto, Ont.) · 2022Article
- A numerical study of the distribution of chemotherapeutic drug carmustine in brain glioblastoma.Drug delivery and translational research · 2022Article
- A state-of-the-art technique to perform cloud-based semantic segmentation using deep learning 3D U-Net architecture.BMC bioinformatics · 2022Review
- Assessment of Optic Nerve Sheath Diameter and Its Postoperative Regression among Patients Undergoing Brain Tumor Resection in a Tertiary Care Center.Journal of neurosciences in rural practice · 2022Article
- Review
- Texture, Morphology, and Statistical Analysis to Differentiate Primary Brain Tumors on Two-Dimensional Magnetic Resonance Imaging Scans Using Artificial Intelligence Techniques.Healthcare informatics research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
This review addresses the specific contributions of nuclear medicine techniques, and especially positron emission tomography (PET), for diagnosis and management of brain tumors. (18)F-Fluorodeoxyglucose PET has particular strengths in predicting prognosis and differentiating cerebral lymphoma from nonmalignant lesions. Amino acid tracers including (11)C-methionine, (18)F-fluoroethyltyrosine, and (18)F-L-3,4-dihydroxyphenylalanine provide high sensitivity, which is most useful for detecting recurrent or residual gliomas, including most low-grade gliomas. They also play an increasing role for planning and monitoring of therapy. (18)F-fluorothymidine can only be used in tumors with absent or broken blood-brain barrier and has potential for tumor grading and monitoring of therapy. Ligands for somatostatin receptors are of particular interest in pituitary adenomas and meningiomas. Tracers to image neovascularization, hypoxia, and phospholipid synthesis are under investigation for potential clinical use. All methods provide the maximum of information when used with image registration and fusion display with contrast-enhanced magnetic resonance imaging scans. Integration of PET and magnetic resonance imaging with stereotactic neuronavigation systems allows the targeting of stereotactic biopsies to obtain a more accurate histologic diagnosis and better planning of conformal and stereotactic radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.